Bioson Pharmaceutical is showing strong intraday gains following news that it received an 'unqualified' opinion from an external auditor on last year's financial statements.
As of 10:26 AM on the 29th, Bioson Pharmaceutical's stock price is at 1,137 KRW, up 13.13% compared to the previous trading day. The stock surged to as high as 1,267 KRW during the session.
The day before, Bioson Pharmaceutical announced that it received an unqualified audit opinion from Hyundai Accounting Corporation. Bioson Pharmaceutical completed the domestic Phase 3 clinical trial of the non-narcotic analgesic injection 'Opirangerin (VVZ-149)' and announced results statistically proving its efficacy in postoperative pain relief. Based on the clinical results, Bioson Pharmaceutical plans to apply for product approval from the Ministry of Food and Drug Safety.
A company representative stated, "Although we disclosed a delay in submitting the audit report on the 22nd and there were some concerns regarding the audit opinion, these were resolved with the unqualified opinion. We will further supplement and improve our internal accounting management system to manage it more transparently in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
